Coya Therapeutics, Inc.
COYA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.95
KIRA · Stoqly’s AI analyst, in plain words
- Coya Therapeutics, Inc. had $7.9M of revenue in fiscal 2025, up 123.6% on the year before.
- Its operating margin was −283.9%, up 201.5 pts: of every 100 in sales, about −284 is left after running the business.
- Coya Therapeutics, Inc. lost $21.2M in fiscal 2025.
Market cap
$92.7M
P/E
—
Revenue
$7.9M
Net income
−$21.2M
Free cash flow
—
Operating margin
−283.9%
Coya Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+123.6%
Yes. Sales grew 123.6% last year.
Does it make a profit?
−267.1%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Coya Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Coya Therapeutics, Inc.
- CIK
- 0001835022
Coya Therapeutics, Inc. · COYA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $6.0M | $3.6M | $7.9M |
| Revenue growth | — | — | — | −40.8% | 123.6% |
| Operating margin | — | — | −131.7% | −485.3% | −283.9% |
| Net income | −$4.9M | −$12.2M | −$8.0M | −$14.9M | −$21.2M |
| Net margin | — | — | −133.1% | −418.7% | −267.1% |
| Diluted EPS | −$1.89 | −$4.73 | −$0.79 | −$0.98 | −$1.27 |
| Cash | |||||
| Cash from operations | −$3.9M | −$7.2M | −$11.2M | −$10.3M | −$10.7M |
| Share count change | — | 0.0% | 292.4% | 49.9% | 9.8% |
| Debt and strength | |||||
| Cash and short-term investments | $4.3M | $5.9M | $32.6M | $38.3M | $46.8M |
| Shareholders' equity | $3.6M | −$8.4M | $35.6M | $39.6M | $43.0M |
| Current ratio | 4.0x | 1.9x | 8.2x | 11.6x | 8.5x |
| Returns and quality | |||||
| Return on equity | −134.3% | — | −58.6% | −39.6% | −51.4% |
| Return on tangible equity | −134.3% | — | −22.4% | −37.6% | −49.3% |
| Piotroski F-score | — | — | 3 | 2 | 2 |
| Altman Z'' | −2.6 | −12.7 | 9.1 | 9.1 | 5.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Coya Therapeutics, Inc. · COYA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.95 a share, the company is worth $92.7M.
Source: SEC EDGAR XBRL filings (CIK 0001835022). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.